NICE adds Baraclude to hepatitis B list
This article was originally published in Scrip
Bristol-Myers Squibb's Baraclude (entecavir) has been confirmed as a treatment option for patients in the national health service in England and Wales with chronic hepatitis B. The National Institute for health and Clinical Excellence's final analysis found the product to be clinically effective at an acceptable cost in both HBeAg-positive and HBeAg-negative patients, despite earlier reservations about its cost-effectiveness in the latter group (Scrip Online, April 10th, 2008).
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.